Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Health Catalyst (HCAT) EBITDA (2018 - 2026)

Health Catalyst filings provide 9 years of EBITDA readings, the most recent being -$102.5 million for Q1 2026.

  • On a quarterly basis, EBITDA fell 518.41% to -$102.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$231.8 million, a 328.67% decrease, with the full-year FY2025 number at -$145.9 million, down 155.86% from a year prior.
  • EBITDA hit -$102.5 million in Q1 2026 for Health Catalyst, down from -$82.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$10.6 million in Q3 2024 to a low of -$102.5 million in Q1 2026.
  • Median EBITDA over the past 5 years was -$29.7 million (2023), compared with a mean of -$32.3 million.
  • Biggest five-year swings in EBITDA: soared 59.56% in 2024 and later crashed 518.41% in 2026.
  • Health Catalyst's EBITDA stood at -$33.5 million in 2022, then increased by 11.51% to -$29.7 million in 2023, then soared by 52.16% to -$14.2 million in 2024, then tumbled by 478.03% to -$82.1 million in 2025, then fell by 24.85% to -$102.5 million in 2026.
  • The last three reported values for EBITDA were -$102.5 million (Q1 2026), -$82.1 million (Q4 2025), and -$13.7 million (Q3 2025) per Business Quant data.